MaxCyte, Inc. Webinar: non-viral cell engineering (5521H)
November 16 2018 - 2:00AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 5521H
MaxCyte, Inc.
16 November 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte to host webinar:
"Non-viral cell engineering: enabling a therapeutic
revolution"
Gaithersburg, Maryland - 16 November 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and life sciences company,
will host a webinar, entitled "Non-viral cell engineering: enabling
a therapeutic revolution," for investors and sell-side analysts
between 15:00 - 16:00 GMT on Tuesday 20(th) November 2018.
MaxCyte has established itself as a world leader in non-viral
cell engineering - offering a rapid, safe and clinically-focused
means of delivering the next generation of cell-based therapies,
which is underlined by the Company's recent commercial and research
partnerships with leading biotech companies including Kite, a
Gilead Company; CRISPR Therapeutics; and Precision BioSciences.
This webinar will showcase and explain how MaxCyte's technology
enables its partners to unlock the potential of their cutting-edge
product development programs by giving them the means to create
drugs using gene-editing technology in the treatment of inherited
genetic diseases and cancer without using viral-vectors, which can
be complicated and expensive to manufacture.
"Recent years have seen the emergence of a remarkable new class
of cell-based therapies targeting many indications - from
ultra-rare diseases affecting a handful of patients to some of the
most common forms of cancer," said Doug Doerfler, President &
CEO of MaxCyte, Inc. "These therapies are made possible by the
extraordinary vision of scientists and clinicians and by a common
core capability, the ability to engineer cells for patients."
"MaxCyte is at the forefront of this revolution in therapeutics
and brings a uniquely powerful, validated and differentiated
approach to cell engineering that is enabling pioneers in the
industry to develop these new treatments as well as powering
MaxCyte's own therapeutic development programs," he added.
MaxCyte's business model provides not only a stable and growing
recurring revenue stream from its technology access fees and
disposable sales but offers significant medium- and long-term
upside from potential milestone- and sales-based payments from its
partners' therapeutic development programs. This has been
demonstrated in the licence agreements recently entered into with
CRISPR Therapeutics and Precision Biosciences. Milestones for
MaxCyte's clinical licenses are generally followed by sales-based
payments as products using MaxCyte's technology progress to
commercialization.
The webinar will be followed by a Q&A session.
Please contact maxcyte@consilium-comms.com if you would like to
attend. Log-in details and a detailed agenda for the webinar will
be provided in advance of the event.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology
platform to enable its biopharmaceutical industry partners to
advance the development of innovative, cutting-edge medicines,
particularly in cell therapy, including the use of gene editing
tools in the treatment of inherited genetic diseases and
immuno-oncology approaches to treating cancer. The Company has
placed its cutting-edge flow electroporation instruments worldwide,
including with nine of the top ten global biopharmaceutical
companies, and has more than 55 partnered programme licences in
cell therapy including more than 25 licensed for clinical use. With
its robust delivery technology, MaxCyte helps its partners to
unlock the full potential of their products. For more information,
visit www.maxcyte.com.
MAXCYTE CONTACTS:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker +44 (0)20 7886
Panmure Gordon 2500
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns
Financial PR Adviser +44 (0)203 709
Consilium Strategic Communications 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGCCGUPRPPA
(END) Dow Jones Newswires
November 16, 2018 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024